Clinical Trials on Red Blood Cell Disorder in Australia

Total 1829 results

Johnson & Johnson Pharmaceutical Research & Development...
Janssen-Cilag International NV

Completed

Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure (PRIMS)

Chronic Kidney Failure | Pure Red-Cell Aplasia

Poland, United Kingdom, Belgium, Germany, Spain, Portugal, Australia, Switzerland, Finland, Greece, Sweden, Netherlands, Norway, Ireland, Denmark
Pharmaxis

Recruiting

Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

REM Sleep Behavior Disorder

Australia, United Kingdom
Boston Children's Hospital

Recruiting

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO (TITRE)

Extracorporeal Membrane Oxygenation | Red Blood Cell Transfusion | Organ Failure, Multiple

United States, Canada, Australia
Australasian Leukaemia and Lymphoma Group

Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX)

Mantle Cell Lymphoma | Mantle Cell Lymphoma Refractory

Australia
TG Therapeutics, Inc.

Completed

Study of TG-1801 in Subjects With B-Cell Lymphoma

B-Cell Lymphoma

Australia
Dizal Pharmaceuticals

Not yet recruiting

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

Australia
Celgene Corporation

Completed

A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Ireland, Spain, Australia, Austria, United Kingdom
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society

Completed

ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells

Multiple Myeloma | Cutaneous Lymphoma

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)

Recruiting

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | MALT Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Indolent Lymphoma | Refractory B-Cell Lymphoma

United States, Australia, China
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

CLL | B Cell NHL

Australia
Peter MacCallum Cancer Centre, Australia
Novartis

Active, not recruiting

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma (TARMAC)

Mantle Cell Lymphoma Recurrent

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (EpiBrentlen)

Hodgkin Lymphoma | Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

Australia
Iksuda Therapeutics Ltd.

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin Lymphoma

Australia, Canada, United States
Peter MacCallum Cancer Centre, Australia
Hoffmann-La Roche

Active, not recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION)

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

Australia
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia
Celgene

Completed

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Melanoma | Lymphoma | Multiple Myeloma | Pancreatic Cancer | Non-Small Cell Lung Cancer

Australia
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Merck Sharp & Dohme LLC

Terminated

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (VEIL)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

Australia
Novartis

Completed

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Myelodysplastic Syndromes | Hemoglobinopathies | Diamond-Blackfan Anemia | Transfusional Iron Overload | Other Inherited or Acquired Anaemia | MPD Syndrome | Other Rare Anaemias

Australia
Peter MacCallum Cancer Centre, Australia
Melbourne Health

Completed

NMP in Relapsed / Refractory Myeloma

Multiple Myeloma

Australia
Bayside Health

Terminated

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

Spain, Australia, Denmark, Norway
Bayside Health

Unknown

Atorvastatin in Myeloma

Myeloma

Australia
Ichnos Sciences SA

Not yet recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
The Leukemia and Lymphoma Society

Completed

A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone

Lymphoma | Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation

Unknown

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Multiple Myeloma

Australia
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
Peter MacCallum Cancer Centre, Australia
Celgene Corporation; Janssen-Cilag Ltd.

Unknown

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia
Janssen, LP

Recruiting

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (CARAMEL)

Extramedullary Myeloma

Australia
AbbVie

Withdrawn

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Multiple Myeloma

Australia
Peter MacCallum Cancer Centre, Australia

Active, not recruiting

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

Mantle Cell Lymphoma

Australia
Gilead Sciences

Terminated

Efficacy Study of CYT997 in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Australia
Cancer Trials Australia
Human Genome Sciences Inc.

Unknown

A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia

Symptomatic Waldenstroms Macroglobulinaemia

Australia
Austin Health
AstraZeneca; Olivia Newton-John Cancer Research Institute

Completed

A Trial of Radiotherapy and Durvalumab in DLBCL and FL (RaDD)

Follicular Lymphoma | Diffuse Large B Cell Lymphoma

Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene

Completed

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Chronic Lymphocytic Leukemia | CLL

Austria
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Australia
Melbourne Health

Recruiting

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Plasma Cell Myeloma | Non-hodgkin Lymphoma | Leukemia, Lymphoblastic, Acute, L1 | Leukemia, Lymphoblastic, Acute, L2

Australia
Peter MacCallum Cancer Centre, Australia
Janssen-Cilag Ltd.

Completed

Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

Multiple Myeloma

Australia
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

B-cell Lymphoma

Australia
Austin Health
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP)

Lymphomas Non-Hodgkin's B-Cell

Australia
Trans Tasman Radiation Oncology Group
Peter MacCallum Cancer Centre, Australia; Australasian Leukaemia and Lymphoma...

Unknown

Involved Field Radiotherapy for Non-gastric Marginal Zone Lymphoma

Non-gastric Marginal Zone Lymphoma

Australia
Institute of Cancer Research, United Kingdom
Australasian Leukaemia and Lymphoma Group

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma

Lymphoma

Australia, United Kingdom
Karyopharm Therapeutics Inc

Terminated

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)

Australia, Singapore
Eli Lilly and Company

Completed

A Study for Patients With Non-Hodgkin's Lymphomas

T-Cell Lymphoma | B-Cell Lymphoma

Mexico, United States, Australia, Brazil, Peru
Bayside Health
Monash University

Recruiting

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

Lymphoma, Non-Hodgkin | Multiple Myeloma | HIV | Chronic Lymphocytic Leukemia | Organ Transplantation | COVID-19 Vaccines

Australia
Peter MacCallum Cancer Centre, Australia

Completed

Panobinostat Biological Correlates Study (VEG VCA1)

Multiple Myeloma | Nodal Lymphoma | Lymphoma With Cutaneous Involvement | Lymphoma in Leukemic Phase | Marrow Involvement With Lymphoma

Australia
Arbeitsgemeinschaft medikamentoese Tumortherapie

Terminated

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

ALK+ Anaplastic Large Cell Lymphoma

Austria
Protalex, Inc.

Terminated

Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP

Idiopathic Thrombocytopenic Purpura (ITP)

Australia, New Zealand
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
Novartis Pharmaceuticals

Completed

Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases

Bone Neoplasms

Australia

Clinical Trials on Red Blood Cell Disorder in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations